Chinese Journal of Clinical Pharmacology and Therapeutics ›› 1996, Vol. 1 ›› Issue (1): 71-73.
Previous Articles Next Articles
Received:
1996-01-20
Revised:
1996-05-28
Online:
1996-03-26
Published:
2020-12-03
CLC Number:
1 Shemer LB,Rosenberg B, Marather VD. Estima-tion of population characteristics of pharnacokinetic paraneters from routine clinical data.J Pharmacokin Biopharm, 1977, 5:445 2 Shener LB, Beal SL. Evaluation of methods for estimating population pharnlacokietic paranelers. Ⅰ. Michaelis - Menten Model:Routine Clinical Phar-macokinetic data. J Pharmacokin Biopharm, 1980, 8:553 3 Sheiner LB,Beal Sl. Evaluation of methods for es-timating populalion pharnacokinelic paranleters Ⅴ. Biexpronential model and exponenlial pharnarokinetic data Pharmacokin Biopharm, 1981, 9:635 4 Sheiner LB, Beal SL. Evaluation of methods for es-timating popuplation pharnlacokinetic paramelers Ⅲ. monoexponential model:Routine cliriical pharma-cokinetie data. J Pharmnacokin Biopharm, 1983,ll:303 5 Schonebeck J, Polak A, Fernex M, et al. Pharma-cokinetic studies on the oral antimycotic agnel 5-fluorocytosine in individuals with normal and inpaired kidney function. Chemotherapy, 1973,18:321 6 Perrier D and Gibaldi M. Estimation of drug elimi-nation in renal failure. J Clin Pharmacol, 1973, 13:458 7 Jones WN and Perrier D. Prediction of creatinine clearance. Am J Hosp Pharm, 1978, 35:1183 8 Gibaldi M and Perrier D. Pharmacokinetics Marcel. Dekker Inc. New York, 1981:396 9 曾衍霖.临床药代动力学群体及个体参数的估外.中国临床药理学杂志,1986, 2(1):24 10 陈刚,卢建丰.一步法估引茶碱群体药代动力学参数.中国药学杂志,1991, 26(11):659 11 夏东亚,王旭东,赵庆春,等.群体药代动力学参数法预测丁胺卡那霉素的个体化给药方案.中国药学杂志,1993, 28(9):546 12 李珍,陈刚.三种估算茶碱群体药动学参数方法的评价.中国药学杂志,1993, 28(8):475 |
[1] | LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282. |
[2] | LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke. A bioequivalence study of generic and brand clozapine in schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130. |
[3] | WANG Fei, HANG Yongfu, WANG Wei. Influence of argumented renal clearance on teicoplannin serum concentrations in critical ill patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1043-1048. |
[4] | HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang. Comparison of calculation results of five population pharmacokinetic analysis tools [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535. |
[5] | LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua. Research progress in population pharmacokinetics of rituximab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474. |
[6] | YAN Qiangyong, XIANG Daxiong, ZHU Ronghua, YANG Lingfeng, YANG Xiding, LI Jingjing, FAN Xiao, LIU Sai, XIONG Shoujun, FANG Pingfei. Bioequivalence study of cinacalcet hydrochloride tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 171-177. |
[7] | YE Hongbo, SONG Yangyang, XUE Ling, RUI Jianzhong. Meropenem population pharmacokinetic model for the Chinese elderly established by model-based META analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 984-990. |
[8] | DU Wenpeng, AO Jiangen, TAO Yi, WU Guansheng, HE Jiake. Study on the factors affecting the steady-state blood concentration of tacrolimus in patients with autoimmune diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 645-651. |
[9] | LIAN Jinfang, LIU Yiwei, LIN Cuihong, HUANG Pinfang, LIN Rongfang. Comparison of prediction accuracy between warfarin PPK/PD model and multiple regression dose models [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 267-273. |
[10] | WU Juan, WANG Zhiqiang, ZHOU Renpeng, YANG Jingjing, QIN Huiling, ZHANG Qian, LU Chao, HU Wei. Bioequivalence trial of fasting oral sorafenib tosylate tablets in healthy Chinese subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 281-286. |
[11] | HU Yin, YANG Dandan, XU Yichao, SHAO Rong, RUAN Zourong, JIANG Bo, CHEN Jinliang, LOU Honggang. Application of artificial neural network model in bioequivalence study of candesartan cilexetil tablets [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 63-69. |
[12] | LIU Chang, DENG Kunhong, HUANG Jie, YANG Shuang, YANG Xiaoyan, XIANG Yuxia, HUANG Lu, ZHANG Zeyu, LIANG Wenzhong, LAN Jing, YANG Guoping. Bioequivalence of moxifloxacin hydrochloride tablets in healthy Chinese subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1393-1399. |
[13] | HAN Guijuan, JIANG Ji, OUYANG Weiwei, LUO Hong, ZHANG Xiaojun, WANG Minghua. Absorption and excretion of CT-707 in healthy male subjects studied by radioisotope tracer method [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1407-1412. |
[14] | LI Na, HAN Hongcan, WANG Jun. General considerations for bioequivalence studies with pharmacokinetic methods for anti-schizophrenic drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1419-1425. |
[15] | ZHANG Miao, LIU Qian, YAO Xueting, LIU Dongyang. Exploration of early food effect study of innovative drugs based on physiologically-based pharmacokinetic absorption model [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1426-1429. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||